ANG Lifesciences India Ltd has closed its trading window for insiders, designated persons, and their immediate relatives effective July 1, 2026. The closure is enforced to comply with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The window will remain shut until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

The company has advised all designated persons and their immediate relatives to refrain from trading in the company's securities during this closure period. This measure is intended to prevent insider trading and ensure market integrity during the sensitive period surrounding financial results.

Regulatory Compliance

The trading window closure is a standard procedure implemented ahead of quarterly financial announcements. It aligns with the requirements set forth by the Securities and Exchange Board of India (SEBI) under the Prohibition of Insider Trading Regulations.

Key Dates and Details

The board meeting to consider the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, will be announced at a later date. The filing was signed by Rajesh Gupta, Managing Director.

ANG Lifesciences India Limited narrowed its consolidated net loss to ₹1,108.48 lakh for the financial year ended March 31, 2026, compared to a loss of ₹1,241.33 lakh in the previous year. The company reported a consolidated revenue from operations of ₹9,289.28 lakh for FY26, marginally higher than the ₹9,284.66 lakh recorded in the corresponding period last year. On a standalone basis, the company posted a net loss of ₹472.64 lakh for the year, an improvement from the loss of ₹1,034.29 lakh in FY25, with standalone revenue rising to ₹9,160.45 lakh from ₹8,991.01 lakh.

Financial Performance

The board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026. For the quarter ended March 31, 2026, the standalone net profit stood at ₹110.25 lakh, while the consolidated entity reported a net loss of ₹138.18 lakh. Total equity for the consolidated entity decreased to ₹5,288.94 lakh as of March 31, 2026, from ₹6,397.59 lakh a year earlier.

Auditor Observations

Statutory auditors M/s Khurana Sharma & Company issued an unmodified opinion on the financial results. However, the auditors included an emphasis of matter paragraph highlighting several compliance issues. The company reported defaults on borrowings from HDFC Bank, including cash credit, GECL, and car loans, with a total outstanding default of ₹1,344.16 lakh for the standalone entity and ₹2,586.45 lakh for the group as of March 31, 2026. Additionally, the auditors noted that undisputed statutory dues, including Employees' State Insurance and Provident Fund, remained unpaid for a period exceeding six months.

Key Financial Metrics

The following table summarizes the standalone and consolidated financial performance for the year ended March 31, 2026:

Segment Reporting

The company operates across two primary segments: Pharmaceuticals and Printing and Packaging. The Pharmaceuticals segment generated a revenue of ₹9,160.45 lakh for the year, while the Printing and Packaging segment contributed ₹486.22 lakh. The total segment revenue stood at ₹9,646.67 lakh before inter-segment eliminations. The auditors also noted that the company had not appointed an internal auditor under Section 138 of the Companies Act, 2013.